FRANKFURT, Jan 29 (Reuters) - Roche <ROG.S> said on Thursday it expects 2026 group sales to grow in the mid single-digit percentage range, while targeting core earnings per share growth in the high
Roche Reports 5% Increase in Earnings Amid Currency Challenges
Roche's Financial Performance Overview
By Ludwig Burger
Operating Income and Market Expectations
FRANKFURT, Jan 29 (Reuters) - Roche's full-year adjusted operating income rose by a lower-than-expected 5% as gains in drugs such as Phesgo against breast cancer and Hemlibra against haemophilia were partly offset by a weak U.S. dollar weighing on overseas sales.
Future Sales and Earnings Projections
Operating profit, adjusted for special items, came in at 21.8 billion Swiss francs ($28.5 billion) in 2025, the Swiss drugmaker said in a statement on Thursday, just shy of a market consensus of 22 billion francs cited by analysts.
The group also said it expects 2026 group sales to grow in the mid single-digit percentage range, while targeting core earnings per share growth in the high single-digit range.
(Reporting by Ludwig Burger, Editing by Friederike Heine)
